Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis

A Phase IV Interventional Study to Assess the Disease-Modifying Effect of Long-Term Treatment With Tildrakizumab in Adult Patients With Moderate-To-Severe Plaque Psoriasis (MODIFY)

The purpose of this study is to evaluate the psoriasis disease control over time in participants who had received Tildrakizumab for at least the last 5 years and have discontinued it and to describe blood and skin inflammatory biomarkers and its correlation disease relapse.

Inclusion Criteria:

• Participants provide signed written informed consent prior to perform any study-related activity
• Participants has completed the long-term extension of the reSURFACE 2 study

Exclusion Criteria:

• Participants unable to comply with the requirements of the study
• Participants who in the opinion of the investigator should not participate in the study